Valeant’s OTC Pickups Emphasize Specialty Segments, Growth Markets
This article was originally published in The Tan Sheet
Executive Summary
The Montreal pharma company includes a focus on OTCs and generics in its quest to grow while remaining relatively immune to patent cliffs and scaled-back Rx reimbursements. Valeant’s recent PEDiNOL Pharmacal acquisition, including OTC podiatry products, fits into its niche category strategy.
You may also be interested in...
Russian Supplement Regulation Demands Careful Navigation
In a guest commentary, Alexey Petrenko, a regulatory consultant in Eastern Europe, notes that Russia has emerged as a driver of growth in the global supplement market with double-digit compound annual growth over the past 10 years. But given the regulatory landscape, firms should be vigilant in staying abreast of how authorities are interpreting rules and where they are targeting their efforts.
Russian Supplement Regulation Demands Careful Navigation
In a guest commentary, Alexey Petrenko, a regulatory consultant in Eastern Europe, notes that Russia has emerged as a driver of growth in the global supplement market with double-digit compound annual growth over the past 10 years. But given the regulatory landscape, firms should be vigilant in staying abreast of how authorities are interpreting rules and where they are targeting their efforts.
Emerging Views On Emerging Markets: Goldman Sachs Health Care Conference
PharmAsia News takes a closer look at presentations by Abbott, Amgen, Medtronic, Mylan, Shire, Stryker and Valeant.